KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accumulated Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Accumulated Expenses for 16 consecutive years, with $156.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 21.22% to $156.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $156.2 million through Dec 2025, up 21.22% year-over-year, with the annual reading at $156.2 million for FY2025, 21.22% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $156.2 million at Halozyme Therapeutics, up from $111.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $156.2 million in Q4 2025, with the low at $16.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $85.6 million, with a median of $98.1 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses crashed 39.96% in 2021, then skyrocketed 336.34% in 2022.
  • Over 5 years, Accumulated Expenses stood at $24.4 million in 2021, then soared by 308.17% to $99.8 million in 2022, then grew by 0.92% to $100.7 million in 2023, then grew by 27.98% to $128.9 million in 2024, then rose by 21.22% to $156.2 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $156.2 million, $111.2 million, and $115.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.